Orion Corporation's Interim Report Release and Webcast
Orion Corporation has exciting updates as it prepares to publish its Interim Report for January–September. This important announcement is scheduled for a release on a designated Tuesday, with the expectation that it will take place around noon EET. Investors and interested parties can access the release along with the necessary presentation materials directly on the company’s investor relations page.
Upcoming Webcast and Conference Call
On the same day as the report, a live webcast and conference call is set for 13.30 EET. This event provides a fantastic opportunity for analysts, investors, and media representatives to engage directly with the company's leadership. The link to the live event will be available on Orion's website, with a recording accessible shortly after the event concludes.
Joining the Conference Call
If you wish to join the conference call, registration is essential. This can be completed online, and specific dial-in details will be provided post-registration. Participants who have questions during the live session can easily raise them by pressing *5 on their dial pad, ensuring an interactive experience.
Maintaining Transparency During the Silent Period
Reflecting its commitment to corporate transparency, Orion Corporation is currently in a silent period leading up to this significant publication. This quiet phase ensures that all information released is disclosed in a fair and organized manner, reinforcing the integrity of the company’s communications.
Contact Details for Investor Relations
Should you have questions or require further information, Orion’s Investor Relations team is more than happy to assist. The primary contact for inquiries is Tuukka Hirvonen, whose dedication to helping investors is evident through the resources they offer. Investors can reach him directly via phone.
About Orion Corporation
Founded over a century ago, Orion Corporation is a leading Nordic pharmaceutical company that has established a strong reputation for enhancing well-being. With a focus on both human and veterinary pharmaceuticals, Orion boasts a robust range of proprietary and generic medications, as well as consumer health products. The company’s research primarily centers on oncology and pain management, with their innovative treatments playing a vital role in addressing complex health challenges. By 2024, Orion's impressive net sales reached EUR 1,542 million, supported by a dedicated workforce of about 3,700 professionals committed to advancing health and wellness initiatives. Notably, Orion's A and B shares are listed on Nasdaq Helsinki, reflecting their prominent standing in the pharmaceutical market.
Frequently Asked Questions
What is the purpose of the interim report for Orion Corporation?
The interim report provides an update on the financial performance and strategic direction of Orion Corporation for the specified period, offering insights to investors.
How can I access the webcast?
You can access the webcast by visiting Orion's investor relations page on the company’s website closer to the event date.
Who can join the conference call?
The conference call is open to analysts, investors, and media representatives who register in advance.
What types of products does Orion Corporation develop?
Orion develops a variety of human and veterinary pharmaceuticals, including treatments for oncology, pain management, and respiratory diseases.
What details are available about Orion's financial performance?
In the previous year, Orion reported net sales of EUR 1,542 million, reflecting its robust market presence and commitment to health solutions.
